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Abstract: Diagnostic tools appropriate for undertaking
interventions to control helminth infections are key to
their success. Many diagnostic tests for helminth infection
have unsatisfactory performance characteristics and are
not well suited for use in the parasite control programmes
that are being increasingly implemented. Although the
application of modern laboratory research techniques to
improve diagnostics for helminth infection has resulted in
some technical advances, uptake has not been uniform.
Frequently, pilot or proof of concept studies of promising
diagnostic technologies have not been followed by much
needed product development, and in many settings
diagnosis continues to rely on insensitive and unsatisfac-
tory parasitological or serodiagnostic techniques. In
contrast, PCR-based xenomonitoring of arthropod vectors,
and use of parasite recombinant proteins as reagents for
serodiagnostic tests, have resulted in critical advances in
the control of specific helminth parasites. The Disease
Reference Group on Helminths Infections (DRG4), estab-
lished in 2009 by the Special Programme for Research and
Training in Tropical Diseases (TDR) was given the mandate
to review helminthiases research and identify research
priorities and gaps. In this review, the diagnostic
technologies relevant to control of helminth infections,
either available or in development, are reviewed. Critical
gaps are identified and opportunities to improve needed
technologies are discussed.
Introduction
The technical limitations of currently available diagnostic
methods for helminth infections impose significant constraints on
current initiatives to control these infections, as discussed in other
reviews of this collection [1,2]. Appropriate diagnostic methodol-
ogies are required for: a) disease mapping to guide initiation and
prioritisation of interventions; b) monitoring and evaluation
(M&E) of ongoing interventions, and particularly for the prompt
detection of possible emerging anthelmintic resistance; c) assess-
ment of elimination of infection by elimination programmes as
these approach termination; and d) case-based diagnosis for
surveillance.
For each of these activities, the technical requirements for
diagnostic tests differ and pose different technical challenges.
Furthermore, for each helminth species, the biology of the parasite
(life cycle, accessibility of parasite stages for parasitological
diagnosis, body fluid appropriate for sampling, role of and need
to sample vector or intermediate host), and of the parasite–host
system (including age profiles of infection prevalence and intensity)
impose different constraints on diagnostic capacity. In addition,
intensity of infection is a critical determinant of transmission
dynamics, morbidity, and disease burden. Thus, the need to assess
infection burden is critical to understanding density-dependent
regulatory mechanisms of parasite transmission and morbidity.
Yet, with few exceptions, this critical parameter is difficult to
quantify accurately with current diagnostic tools.
Not only are techniques for the diagnosis of individual infections
important, but also techniques for assessment in communities and
larger regions are necessary. In this respect, a major obstacle to the
implementation of cost-effective control is the lack of accurate
descriptions of the geographical distribution of infection. The
effectiveness of large-scale integrated programmes for the control
of neglected tropical diseases (NTDs) in general, and helminth
diseases in particular, depends on appreciation of the geographical
overlap between the different NTDs. However, in spite of being
co-endemic in most countries, different NTDs can exhibit limited
geographical overlap at sub-national scales, necessitating a more
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geographically targeted approach for their control. Therefore,
techniques appropriate for the diagnosis and surveillance of
helminth infections are essential for solving many of the control
challenges described in other articles of this collection [1,2].
The range of diagnostic tools that are available at present can be
classified into: 1) parasitological tests, where the parasite (or more
frequently parasite transmission stages), sampled from appropriate
tissues or body fluids, is directly visualised using a microscope (not
necessary for visualisation of large nematodes such as adult Ascaris);
2) serological assays, where parasite-specific antibodies are detected
in serum samples; 3) antigen detection tests, where a parasite
biomarker is detected; 4) molecular diagnosis, where parasite
nucleic acid is detected; and 5) other specific tools for parasite
detection in arthropod vectors or snail (or other) intermediate hosts.
As noted above, there are important differences in the specific
requirements for diagnostic tests for each helminth parasite,
differences that are determined by the biology of the parasite and
the control interventions that are currently deployed. Likewise, the
critical gaps in diagnostic technology differ for each parasite species.
In this review, a product of the discussions held by the Disease
Reference Group on Helminth Infections (DRG4) established in
2009 by the Special Programme for Research and Training in
Tropical Diseases (TDR), available diagnostic tests for the six
helminth human infections, within the remit of the DRG4, are
considered in the context of the specific technical requirements of
diagnostic tests needed for control of these parasites, and critical
gaps in diagnostic technology are identified. The technical issues
related to the performance of tests using parasitological, serological,
antigen detection, molecular detection, and other specific tools for
diagnosis in vectors and intermediate hosts are detailed in the
following supplementary files: Text S1 for soil-transmitted helmin-
thiases; Text S2 for filarial infections; Text S3 for schistosomiasis;
Text S4 for hydatid disease; Text S5 for taeniasis/cystercosis; and
Text S6 for food-borne trematode infections. A summary of the
current diagnostic tools for monitoring and surveillance in control
programmes is presented in Table 1. The use of these tests in the
context of control and elimination activities is outlined in the
sections below. Box 1 lists the abbreviations used in this paper. The
desired attributes of diagnostic techniques required for the successful
implementation of mass drug administration (MDA) programmes
are listed in Box 2.
Soil-Transmitted Helminthiases
Current control programmes for the intestinal nematodes or
soil-transmitted helminthiases (STHs), namely, those caused by
Ascaris lumbricoides, hookworm (Necator americanus and Ancylostoma
duodenale), and Trichuris trichiura (and to a lesser extent by
Strongyloides stercoralis) are focused on morbidity control through
community-based deworming programmes, particularly among
school-age children by annual or twice annual distribution of a
single dose of a broad spectrum benzimidazole anthelmintic, either
albendazole or mebendazole [2,3]. Although parasitological
diagnosis can be readily undertaken (see below), a number of
critical deficiencies in diagnostic capacity exist. These include the
absence of well-validated and practical methodologies to measure
infection intensity (egg count is taken as a proxy for this but this
approach has limitations), and validated cutoffs for drug efficacy
monitoring [4]. A detailed discussion of the strengths and
weaknesses of diagnostic tests appropriate for diagnosis of STHs
is presented in Text S1, and a summary of the use of current STH
diagnostic tests for specific objectives is presented in Table 2. The
research priorities for STH diagnosis are summarised in Box 3.
Infection Intensity
For the STHs, intensity of infection is a major determinant of
morbidity, infection dynamics, and response to therapy, as well as
Table 1. Diagnostic Tools Available for Monitoring and Surveillance in Control Programmes for Human Helminthiases.
Helminth Infection Stage of the Control Programme References
Early Advanced Final and End Points
Onchocerciasis Nodule palpation for detection
of onchocercomata, skin-snipping
for detection, and counting of
mf in skin snips
Skin snipping sensitivity
decreases; DEC patch test; PCR-
based monitoring of simulid
populations; Ov-16 card test
Xenomonitoring via fly feeding/recording
microfilarial uptake. Serology in untreated
children; PCR and DEC patch test; Ov-16
card test
[106,107]
Lymphatic filariasis Blood smears for detection
and counting of mf in blood;
CFA for bancroftian filariasis.
Rapid dipstick for antibody
(Ab) detection in brugian filariasis
PCR-based assays for W.
bancrofti and B. malayi in blood;
PCR-based monitoring of
mosquito populations
Monitoring infections in mosquitoes and
anti-filarial Ab levels in children as indicators
of local transmission for making decisions
about programme end points
[108–110]
Soil-transmitted
helminthiases
Quantitative egg counts using
validated methodology such as
Kato-Katz (KK) test
Infections become lighter and
more difficult to detect. Egg
concentration techniques, e.g.,
FLOTAC likely to be required
to detect light infections
Increasing proportion of unfertilised Ascaris
eggs could indicate declining mating
probability (unfertilised eggs often missed
by KK). Need for highly sensitive
diagnostic methods
[11–13]
Intestinal schistosomiasis
due to S. mansoni
As above Need to validate PCR-based
diagnostic assays in low-
transmission areas
Elimination of infection reservoir rarely
attempted
[111]
Intestinal schistosomiasis
due to S. japonicum
Initial screening for antibodies
in indirect haemagglutination
assay (IHA), subsequent testing
with KK of the seropositive results
Seroprevalence determined
by IHA can be much higher than
prevalence in stool-based PCR;
hatching and KK tests
New algorithms for treatment in low
intensity areas; PCR may replace KK in
such algorithms. Surveillance in snails;
sentinel mice
[111–114]
Urinary schistosomiasis
(S. haematobium)
Urine filtration for detection and
counting of eggs
Need to improve urine
circulating antigen test for
use in low-transmission areas
Find and treat cases in both active
surveillance and health care settings
[111]
doi:10.1371/journal.pntd.0001601.t001
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a crucial variable for epidemiological modelling [5]. Further,
aggregation of infection, whereby a minority of individuals
harbour very heavy infection loads but the majority of the host
population harbours light or moderate infection, is a major
factor to consider in epidemiological studies and chemotherapy
efficacy trials, as well as in efforts to reduce prevalence. Intensity
of infection would be best assessed by enumerating adult worm
numbers. While this can be achieved by use of a cathartic in
conjunction with an anthelmintic, preferably one that paralyses
adult worms, such as pyrantel pamoate or levamisole, followed
by enumeration of parasites in collected faeces, this is not an
easy test to perform, and is unreliable for hookworms and
whipworms because of poor to moderate, and variable, efficacy
of pyrantel and levamisole against these parasites [6]. Therefore,
most studies and surveys have relied on quantitative egg
counting.
Of the quantitative methods described for egg counting, the
Kato-Katz method [7], originally developed for detection and
quantification of Schistosoma mansoni eggs in human faecal samples,
is the most widely used method, and has undergone a number of
validation studies [8,9]. This test has some methodological
problems due to the fact that different helminth eggs have
different clearing times and viability. Hookworm eggs in particular
are subject to lysis if the slides are not examined within 30 minutes
[10]. A preferred quantitative flotation technique used in
veterinary practice is the McMaster test [4]. It is less well studied
in the human STH infections. In a recently undertaken study
where these two methods were compared, the accuracy of the two
tests was approximately equivalent [4]. The McMaster method
has the drawback of not being suitable for community studies
where intestinal schistosomiasis is co-endemic (China, Africa,
South America). Recently, a purpose-built flotation apparatus
(FLOTAC) has been designed and tested for the purpose of
improving the quantitative analysis of faecal egg counts [11].
Although the FLOTAC method is more sensitive than the Kato-
Katz technique [12,13], particularly for hookworm eggs, it
requires a centrifuge and is relatively low-throughput.
Application of Diagnostics for Assessment of Response to
Anthelmintic Chemotherapy including Detection of
Anthelmintic Resistance
Although quantitative measurement of infection intensity by egg
counting before and after treatment is the best available method
for assessment of anthelmintic efficacy, this approach suffers from
a number of significant drawbacks. For example, the relationship
between worm burden and egg output is not linearly proportional,
with density-dependent fecundity resulting in the potential
underestimation of adult worm burden, for example in A.
lumbricoides and hookworm infection [14–16].
The weaknesses in study design and consequent uncertainties in
measures of STH anthelmintic drug efficacy have been reviewed
[2,17,18]. In a recent review, specific guidelines regarding study
design, including intervals between testing and expected clearance
thresholds, have been recommended [2]. A specific problem is the
lack of inter-study standardisation of diagnostic tests used. Two
other specific issues pertain to technical aspects of diagnosis:
detection of low level infection, especially when a single stool
sample is examined using methods such as Kato-Katz, and a lack
of standardisation of the assessment of reduction in infection
intensity as determined by reduction in faecal egg counts. While
direct parasitological tests are relatively sensitive, their perfor-
mance is suboptimal at low intensity of infection, and therefore a
Box 1. List of Abbreviations
APOC, African Programme for Onchocerciasis Control
CAA, circulating anodic antigen
CCA, circulating cathodic antigen
CFA, circulating filarial antigen
CHD, cystic hydatid disease
DDIA, dipstick dye immunoassay
DEC, diethylcarbamazine
DFID, Department for International Development, United
Kingdom
DRG4, Disease Reference Group in Helminth Infections
FDA, Food and Drug Administration, United States
FECRT, faecal egg count reduction test
FIND, Foundation for Innovative New Diagnostics
GIS, geographical information system
ICT, immunochromatographic test
ITS, internal transcribed spacer
LAMP, loop-mediated isothermal amplification
LF, lymphatic filariasis
LIPS, luciferase immunoprecipitation system
MDA, mass drug administration
MDG, Millenium Development Goal
MDSS, Medical Device Safety Service, European Union
M&E, monitoring and evaluation
mf, microfilariae
NCC, neurocysticercosis
NTD, neglected tropical disease
PCR, polymerase chain reaction
PDIP, Product Development and Implementation Partner-
ship
POC, point-of-care
RAPLOA, rapid assessment procedure of loiasis
R&D, research and development
REA, rapid epidemiological assessment
REMO, rapid epidemiological mapping of onchocerciasis
SAE, severe adverse event
SEA, soluble egg antigen
STH, soil-transmitted helminthiasis
TB, tuberculosis
TDR, Special Programme for Research and Training in
Tropical Diseases
WHO, World Health Organization
Box 2. Five Desirable Attributes of Diagnostic
Tests Required for Helminth Control
Programmes
N Scalable cost-effective tests for individual diagnosis.
Ideally these should be suitable for point-of-care (POC)
use, or in environments where technical resources are
limited
N Tests suitable for large-scale surveys, for example for
epidemiological surveillance
N Tests capable of quantifying infection intensity (worm
burden) reliably, a diagnostic parameter that is critical
when dealing with helminth infections
N Tests enabling quantification of suboptimal responses to
control interventions including prompt detection of
drug resistance
N High specificity and sensitivity as infection prevalence
and intensity decrease throughout intervention, en-
abling to assess programme end points
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single negative stool examination for helminth eggs is liable to
result in Type II errors in evaluation of trial outcomes, i.e.,
misclassification of decreased drug efficacy as intact due to failure
to detect persistent, low level infection following anthelmintic
therapy. As discussed above, while there is no well-accepted
measure of intensity of infection, trials have generally reported
some measure of reduction in egg count, but not in a standardised
fashion. In veterinary practice, significant work has been
undertaken to standardise assessment of anthelmintic drug efficacy
[19], specifically in standardising all aspects of the faecal egg count
reduction test (FECRT). As noted above, assessment of drug
efficacy by reporting reduction in egg counts is, in addition, subject
Box 3. Research Priorities for Helminth Diagnostics
Soil-Transmitted Helminthiases
1. Improve and validate tools for quantifying intensity of
infection (worm burden), including both biomarkers
(coproantigen) and molecular methods (PCR-based)
2. Refine/develop methods to assess response to treatment
for monitoring of drug efficacy
3. Refine methods for more accurate quantification of egg
counts
4. Develop and validate methods for quantifying parasite
genetic diversity and population structure
Filarial Infections
1. Devise diagnostic tools (e.g., biomarkers of active infection)
to assist elimination. Most available diagnostic methods are
too insensitive for M&E and surveillance once infection
prevalence falls to very low levels
2. Develop circulating antigen tests for detection of O.
volvulus, L. loa, and B. malayi infection that can be used
in combination with current tools to assess active infection
3. Identify and validate informative molecular markers for
detection of heritable changes in drug efficacy, and
develop cost-effective tools to detect such changes
4. Develop and validate methods for quantifying parasite
genetic diversity and population structure
Schistosomiasis
1. Refine antigen tests and optimise algorithms for their
combination with existing diagnostic assays including
parasitological, immunological, and ultrasound tools
2. Develop assays for assessment of worm burden in areas of
varying endemicity
3. Identify and standardise markers and assays for resistance
to praziquantel for monitoring of drug efficacy
4. Improve and standardise protocols for monitoring of
infection in humans and snails by molecular methods
5. Develop and validate methods for quantifying parasite
genetic diversity and population structure
Cystic Hydatid Disease
1. Develop rapid, sensitive, and specific point-of-care (POC)
tests for canine echinococcosis
Taeniasis/Cysticercosis
1. Develop rapid, sensitive, and specific POC tests for human
taeniasis
2. Develop sensitive and specific tests for detection of viable
Taenia solium infections in pigs
3. Devise quantitative tests to determine intensity of infection
Food-Borne Trematodiases
1. Develop species-specific monoclonal antibodies suitable
for use in specific coproantigen detection tests
2. Validate effective and inexpensive molecular methods for
differentiation of fluke species with similar egg morphol-
ogy
Table 2. Diagnostics Available for Soil-Transmitted Helminthiases.
Diagnostic Procedure and Objective Species of Intestinal Nematode
Ascaris lumbricoides (roundworm), Trichuris
trichiura (whipworm), Necator americanus/
Ancylostoma duodenale (hookworm) Strongyloides stercoralis (threadworm)
Stool microscopy with or without concentration
stepa
3 +/2
Coproculture Harada Mori for specific identification of hookworms 3
Antibody detection N/A 3
PCR and antigen detection ----Experimental----
Assessment of infection intensity Quantitative fecal egg count; PCR (experimental) N/A
Assessment of drug efficacy Reduction in stool egg counts (FECRT) Negative coproculture; decline in antibody titer
Mapping Stool microscopy Antibody detection
Elimination N/A N/A
aBy sedimentation (e.g., formalin-ethyl acetate sedimentation) or flotation (e.g., ZnSO4).
3, Available or method of choice; N/A, not available; +/2, acceptable but not ideal.
doi:10.1371/journal.pntd.0001601.t002
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to confounding due to the effect of density-dependent fecundity on
egg counts [16]. There may also be considerable geographic
heterogeneity in the strength of density-dependent constraints on
worm fecundity [14].
Pilot phenotypic tests of anthelmintic response have been
developed for hookworms, taking advantage of the characteristic
of hookworm eggs, whereby eggs passed in the faecal stream
mature into infective larvae over a number of days [20–22].
While there has been some work undertaken to standardise such
tests [23], significant work remains to be done. For T. trichiura
and A. lumbricoides, it has not been possible to develop such
phenotypic tests due to the lack of egg hatch in the external
environment, and an inability to readily assess parasite viability
ex vivo.
Some work has been conducted to develop molecular methods
to genotype intestinal nematode parasites for genetic markers of
anthelmintic resistance [24]. Efforts have largely concentrated on
genotyping for specific polymorphisms in the b-tubulin gene that
are recognised to be associated with anthelmintic resistance in a
range of veterinary nematodes, specifically mutations in the b-
tubulin gene at codons 200, 167, and 198. Assay methodologies
have been developed for A. lumbricoides [25], hookworms [26,27]
and T. trichiura [25,28], with resistance-associated mutations being
found in some populations of these soil-transmitted nematodes.
This suggests that selection for resistance to anthelmintics such as
albendazole and mebendazole can occur, and may help explain
the sometimes low and variable efficacy of these anthelmintics
against human STH infections (see [2,24] for recommended cure
efficacies). However, the relationship between the presence and
frequency of these specific mutations and drug response pheno-
types has not yet been fully characterised, and should become an
important research priority so that fast and sensitive genotyping
analyses, used on pooled egg samples, can provide surveillance
tools for anthelmintic resistance.
Application of Diagnostics for Disease Mapping,
Surveillance, and Mathematical Modelling
Infection mapping of STHs has progressed well, and readers are
referred to the http://www.thiswormyworld.org/ website. Al-
though mathematical models of transmission (reviewed within this
collection in [5]) have been developed, they may not account for
current difficulties in accurately quantifying worm burden, a
consideration that is seldom recognised.
Filariases
The programmes to eliminate onchocerciasis from the Americas
and lymphatic filariasis (LF) on a global basis have highlighted
specific deficiencies in the diagnostics for the filariases, particularly
in elimination settings. Some relate to the problem of surveillance
when infection prevalence falls to low levels. In such settings, most
available methods are too insensitive, even if active case detection
were logistically feasible. Other specific issues include prediction of
the risk of severe adverse events (SAEs) when individuals with high
grade microfilaraemia with Loa loa are administered antifilarial
chemotherapy, and detection and management of changes in drug
efficacy that may indicate emerging resistance. A detailed
discussion of the strengths and weaknesses of diagnostic tests
appropriate for diagnosis of filariasis is available in Text S2, and a
summary of current diagnostic tests for filariases is presented in
Table 3. The research priorities for filarial diagnosis are
summarised in Box 3.
Table 3. Diagnostics Available for Filarial Infections.
Objective Lymphatic Filariasis Onchocerciasis Loiasis
Wuchereria bancrofti Brugia malayi Onchocerca volvulus Loa loa
Parasitological diagnosis Blood filtration for microfilariae (mf)
Ultrasound
Skin snip
Nodule palpation
DEC patch test
Blood filtration for
microfilariae
Antibody detection 3 3 3 3
Antigen detection 3 – – –
PCR Molecular xenomonitoring (PCR on mosquito/fly vectors) –
Assessment of infection
intensity
mf load in blood
Antigen level
mf load in blood mf load in skin
Nodule palpation
mf load in blood
Assessment of
drug efficacy
Disappearance of mf from
blood at given times
post-treatment Ultrasound
changes in filarial worm nests
Clearance of circulating antigen
Disappearance of mf
from blood at given
times post-treatment
Ultrasound changes
in filarial worm nests
Disappearance of mf from
skin at given times
post-treatment Ultrasound
changes in nodules By
nodule histology or
embryogram examination
Disappearance of
mf from blood
Mapping Antigenaemia prevalence REMO RAPLOA
Elimination Seroepidemiology Seroepidemiology
Molecular xenodiagnosis of
vectors (mosquito PCR)
Seroepidemiology
Molecular xenodiagnosis
of vectors (blackfly PCR)
N/A
3, Available or method of choice; N/A, not available; –, not available.
REMO, rapid epidemiological mapping of onchocerciasis; RAPLOA, rapid assessment procedure for loiasis.
doi:10.1371/journal.pntd.0001601.t003
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Infection Intensity
Infection intensity may refer to adult worm burden or
microfilarial load. The relationship between microfilarial load, as
assessed by quantification of blood microfilaraemia in LF and
loaisis, or of microfilaridermia by skin snip in onchocerciasis, and
the total adult parasite burden is at best semi-quantitative. In
addition to limitations imposed by sampling methodology and
measurement error, microfilarial load is significantly affected by
immune-mediated parasite clearance mechanisms, and processes
regulating the fecundity of adult worms. Assessment of adult worm
burden in onchocerciasis by nodule palpation suffers from both
sensitivity and specificity problems in addition to complications
brought about by the aggregation of adult worms in nodules.
Nodule prevalence in a sample of adult hosts has been used to
estimate a measure of community infection for onchocerciasis, by
relating nodule to microfilarial prevalence. While palpation of
onchocercal nodules is the major tool for determination of
infection prevalence and rapid epidemiological mapping of
onchocerciasis (REMO) in areas of the African Programme for
Onchocerciasis Control (APOC), where it is used for identification
of communities at risk [29], and for selection of areas for mass
ivermectin administration, it is only reliable in highly endemic
areas. Its diagnostic precision is poor because of large intra- and
inter-individual variability, and its ability to reflect changes in
endemicity as a result of large-scale and prolonged control
programmes is limited [30].
Circulating filarial antigen (CFA) in bancroftian filariasis is a
product of adult worms, with the majority being produced by adult
female worms. As it is very difficult to enumerate adult worm
numbers in humans, the relationship between CFA level and
parasite burden is difficult to establish, but has been achieved in
relevant animal models [31]. In one study, where worm nests were
enumerated by ultrasound, there was a non-significant association
between CFA level and ultrasound signal [32].
Application of Diagnostics for Assessment of Response to
Anthelmintic Chemotherapy including Detection of
Anthelmintic Resistance
Aside from assessment of changes in microfilarial counts
following treatment, diagnostics for establishing cure of filariasis
are generally lacking, and as discussed in [24], the available drugs
for MDA are not generally macrofilaricidal (with the exception of
prolonged courses of doxycycline to deplete Wolbachia endobac-
teria [33]). This is particularly problematic when drugs, with
selective activity on the only life cycle stage that is amenable to
parasitological diagnosis—the microfilariae (mf)—are used (e.g.,
diethylcarbamazine [DEC], ivermectin). Ultrasound to establish
killing of adult worms in nodules in onchocerciasis may produce
equivocal results [34], and in any case, current annual or semi-
annual treatment regimens are not significantly macrofilaricidal.
Thus, assessment of ‘‘cure’’ after ivermectin therapy is problem-
atic, and without other markers it hampers study of possible drug
resistance. One approach has been to profile the responses of
individuals to ivermectin treatment by recording the rates of
reappearance of microfilariae in the skin after drug treatment, with
a faster than expected rate of repopulation serving as an indicator
of suboptimal response [35,36]. A complementary approach is the
histological examination of female worms in nodules removed at
approximately 3 months after ivermectin treatment, or the
preparation of embryograms from the females’ uterine content
to assess resumption of microfilarial production [35,36]. As
ivermectin treatment sterilises adult female worms for a period
after treatment, after several rounds of ivermectin (.4–6 rounds),
the uterus of adult female worms should be free of live, stretched
mf 3 months after treatment. Also, if active transmission is still
ongoing in an area under prolonged ivermectin control, these
methods allow assessment of the presence of young, incoming
worms [37].
In LF, the detection of the ‘‘filarial dance sign’’ in worm nests by
ultrasound has been advocated to determine adult worm viability
after macrofilaricidal chemotherapy (e.g., DEC, anti-Wolbachia
therapy) [38,39]. The disappearance of parasite antigen can also
serve as a surrogate for cure [40].
Application of Diagnostics for Disease Mapping,
Surveillance, and Mathematical Modelling
Given the imperfections of currently available diagnostics for
filariases, particularly with respect to the invasive and insensitive
nature of parasitological diagnosis, and the often critical need to
undertake cost-effective mapping, a number of novel techniques
have been developed to overcome the shortcomings of diagnostics.
For onchocerciasis, REMO began with work to identify proximity
to blackfly breeding sites and community nodule prevalence [29].
More recently, this has been supplemented by PCR screening of
pools of flies [41], and the DEC patch test [42]. A summary of
specific issues in diagnostic testing for onchocerciasis is presented
in Table 4.
For bancroftian filariasis, CFA assays, in the form of
immunochromatographic card tests (ICTs), have been successfully
incorporated into programmes to map the distribution of
Table 4. A Comparison of Current Diagnostic Tests for Human Onchocerciasis.
Test Specificity Sensitivity
Interference by
Onchocerca ochengi Throughput Cost Application
Skin snip #100% Low No Low Low Field
Nodule palpation Moderate Low No High Low Field
Snip PCR #100% #100% No Low High Lab
Scratch PCR #100% #100% No Low High Lab
DEC patch 98% 36%–83% No Low Low Lab
Fly dissection Low Low Yes Low Moderate Field
Fly pool PCR High High No High Varies Lab
Antibody ELISA #100% #100% No High Mod Lab
Modified from Boatin et al. [106].
doi:10.1371/journal.pntd.0001601.t004
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bancroftian filariasis [43,44], but see the introductory article of this
collection for problems with this test [45]. The occurrence of SAEs
following ivermectin distribution in areas where L. loa infection is
highly prevalent [46] has required the development of a model-
based geostatistical methodology [47] to map the risk of L. loa
infection being above a predetermined level (20% prevalence) in
areas co-endemic for onchocerciasis. The first approach was based
on using elevation and remote sensing images to define high-risk
areas based on geographic factors such as vegetation cover and
forest boundaries that defined the limits of breeding of the Chrysops
vector [48]. A second qualitative method, Rapid Assessment
Procedure for Loa loa (RAPLOA) uses a standardised questionnaire
to enquire for history of eye worm or Calabar swelling alone or in
conjunction with confirmation of presence of L. loa microfilarae-
mia in a survey sample [49]. The relationship between prevalence
of microfilaraemia and prevalence of eyeworm passage has been
incorporated into the geostatistical model [50].
Schistosomiases (including Infections by
Schistosoma mansoni, S. haematobium, and S.
japonicum)
To date, most schistosomiasis control programmes have aimed
at morbidity reduction rather than elimination of infection [51].
MDA with praziquantel is the main tool for morbidity control
[52]. As the prevalence of schistosomiasis decreases, the need for
improved diagnostic approaches for surveillance purposes will
significantly increase, and in some environments where the
causative parasite is a zoonosis (S. japonicum), increasing attention
to the animal reservoirs will be required. A detailed discussion of
the strengths and weaknesses of diagnostic tests appropriate for
diagnosis of schistosomiasis is available in Text S3, and a summary
of current diagnostic tests for schistosomiasis is presented in
Table 5. The research priorities for schistosomiasis diagnosis are
summarised in Box 3.
Infection Intensity
Although estimation of the intensity of schistosomiasis infection
is an essential requirement for the implementation of control
programmes, M&E, for assessment of efficacy of anti-bilharzial
drugs, and as the most important determinant of morbidity,
available diagnostics are suboptimal for this purpose.
Quantitative egg counting following urine filtration or Kato-
Katz smear are the standard techniques for estimation of intensity
of Schistosoma infection [53]. However, these methods are
confounded by a number of factors, including the overdispersed
nature of schistosome egg output in stool, and the daily variation
in excretion [54]. It has been recommended that replicate faecal/
urine samples over several (ideally a minimum of three)
consecutive days be used to quantify infection intensity. This
requirement is most important in low endemicity settings, in
monitoring of control programmes, and in chemotherapy efficacy
trials [55–59]. However, such approaches are not logistically or
financially feasible except in research settings. Statistical methods
have been proposed to improve accuracy in the parasitological
estimates [56].
Application of Diagnostics for Assessment of Response to
Anthelmintic Chemotherapy including Detection of
Anthelmintic Resistance
A number of reports from endemic areas have suggested that
resistance or tolerance to praziquantel might exist in S. mansoni in
Egypt [60] and Senegal [61,62], making the need for sensitive
diagnostic techniques for M&E of control programmes and
praziquantel chemotherapy a priority. Monitoring the efficacy of
praziquantel in schistosomiasis has relied on the relatively
insensitive method of measuring reduction in egg excretion
following treatment [63]. In addition to any variations in drug
effect on the worms, several factors can confound the interpreta-
tion of such studies. These include variability in pharmacokinetics
of praziquantel in different individuals, the effect of differences in
immune responses to the worms on drug effect, and the maturity
of worms in the human host (praziquantel is relatively ineffective
against juvenile worms) [64,65]. While a number of approaches to
overcoming the significant impediments to detecting drug
resistance using clinical efficacy as the parameter have been
reported, none are readily deployed at programmatic levels. One
such approach has been to transfer clinical isolates from human
patients into mice for testing [66,67]. While this method has
enabled detailed laboratory study, it is expensive, it requires
sophisticated infrastructure, and is not always successful. A
number of in vitro tests have been developed for testing
praziquantel sensitivity on schistosome parasites at a variety of
life cycle stages [68–72]. However, to date none of these tests have
been standardised.
Application of Diagnostics for Disease Mapping,
Surveillance, and Mathematical Modelling
As schistosomiasis is characterised by focal distribution and
large-scale patterns of transmission that are influenced by
climatic and environmental conditions, the integrated use of
Table 5. Diagnostics Available for Schistosomiasis.
Schistosomiasis
Schistosoma mansoni Schistosoma haematobium Schistosoma japonicum
Parasitological diagnosis Stool Kato-Katz Urine filtration Stool Kato-Katz
Antibody detection 3 3 3
Antigen detection + +/2 N/A
PCR -----Experimental-----
Assessment of infection intensity Stool Kato-Katz Urinary egg count Stool Kato-Katz
Assessment of drug efficacy Clearance of eggs from stool Clearance of eggs from urine Clearance of eggs from stool
Mapping/elimination Seroepidemiology Seroepidemiology Seroepidemiology
3, Available or method of choice; N/A, not available; +/2, acceptable but not ideal.
doi:10.1371/journal.pntd.0001601.t005
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geographical information systems (GIS), remote sensing, and
geostatistics has provided new insights into its ecology and
epidemiology at a variety of spatial scales [73]. Nevertheless,
the microecology of snail and parasite endemicity may not be
readily defined without detailed parasitological surveys [74].
The variability in egg output noted above, and its relationship
with infection prevalence and intensity, has received consid-
erable attention in the development and validation of
mathematical models of schistosomiasis [75,76]. A positive
and statistically significant relationship between serum con-
centration of circulating cathodic antigen (CCA) and circulat-
ing anodic antigen (CAA) (as measures of worm burden) and
egg output has been reported [77], and such relationships have
been used to confirm density-dependent fecundity in S. mansoni
[78]. More recently, attention has focused on modelling the
impact of chemotherapy on parasite genetic diversity and drug
resistance [79–81] as discussed in this collection [5].
Cystic Hydatid Disease
The key interventions for control of cystic hydatid disease
(CHD) are continuous mass chemotherapy with praziquantel
administered to dogs along with changes to husbandry so that raw
offal is not fed to dogs. The development of an efficacious sheep
vaccine (EG95) [82] and promising results from early studies on a
dog vaccine [83] indicate that these interventions will also become
useful tools. There are no standard guidelines for monitoring the
effect of control programmes. A detailed discussion of the strengths
and weaknesses of diagnostic tests appropriate for diagnosis of
cystic hydatid disease is available in Text S4, and the research
priorities for CHD diagnosis are summarised in Box 3.
Infection Intensity
Quantification of the burden of Echinococcus worms in dogs can
be undertaken by egg counting and by worm counting after
arecoline purge. As even a few lightly infected dogs can sustain
infection transmission, due to the high biotic potential of cestodes,
the intensity of infection is a parameter of less importance in
echinococcosis.
Application of Diagnostics for Assessment of Response to
Anthelmintic Chemotherapy including Detection of
Anthelmintic Resistance
As described above, the main control tool is mass chemotherapy
of dogs; thus, surveillance for treatment efficacy in individual dogs,
reinfection rates, or emerging resistance are not priority param-
eters for surveillance. Instead the number and coverage of dog
treatments is the most important variable in control programmes.
Application of Diagnostics for Disease Mapping,
Surveillance, and Mathematical Modelling
The transmission dynamics of E. granulosus have been compre-
hensively studied by Gemmell and co-workers [84]; see also the
modelling review in this collection for other mathematical studies
of the population biology of CHD [5]. Currently, surveillance is
mostly based on infection surveillance at slaughter of infected
sheep for liver or lung cysts or, in the case of control programmes
targeting dogs, coproantigen or copro PCR assessments.
Taeniasis/Cysticercosis
Control of taeniasis/cysticercosis due to Taenia solium is in a
much earlier stage. Pilot intervention studies have been undertak-
en since 1989 using mass chemotherapy of the human population
with praziquantel [85]. In further studies interventions entailing
health education and combined mass human and porcine
chemotherapy have been investigated. More recently, a large-
scale elimination programme was applied in Peru [86] using a
series of tools described below. A detailed discussion of the
strengths and weaknesses of diagnostic tests appropriate for
diagnosis of taeniasis and cysticercosis is available in Text S5,
and the research priorities for taeniasis/cysticercosis diagnosis are
summarised in Box 3.
Infection Intensity
In both porcine and human cysticercosis, most infected
individuals carry a few parasites, and indeed most (.90%) human
tapeworm carriers harbour a single tapeworm, with infections with
more than two tapeworms being extremely rare, and therefore
unlikely to have implications for transmission control. On the
other hand, a high number of brain cysts in a human NCC patient
is usually associated with that person carrying a tapeworm, and
heavy infections in pigs mark the proximity of a human tapeworm
carrier. However, identification of heavily infected humans or pigs
requires brain imaging in humans or necropsy of pigs; thus, their
use in control is very limited. Tongue-positive pigs may serve as a
proxy for heavy cysticercosis infections. Whether transmission of
taeniasis in endemic populations is mostly driven by the majority
of pigs infected with few cysts (and thus difficult to detect), or by
the few pigs with many cysts (potential source of infection to many
people if eaten) is an unknown but important question [87]. A
diagnostic technique to determine intensity of infection in pigs
would therefore prove useful.
Application of Diagnostics for Assessment of Response to
Anthelmintic Chemotherapy including Detection of
Anthelmintic Resistance
Intestinal tapeworm infections are usually cured with a single
dose of niclosamide. The only way to confirm cure is to identify
tapeworm scoleces and proglottids following combined niclosa-
mide and purgative therapy [88], a method that is not widely
practiced. Coproantigen follow up was used for this purpose in the
Peru elimination programme and found to be very efficient. For
cysticercosis, the main way of determining cure is by radiologic
imaging to determine that cysts have been killed, a methodology
not useful for epidemiologic studies. To date, there is no evidence
for anthelminthic resistance in taeniasis.
Application of Diagnostics for Disease Mapping,
Surveillance, and Mathematical Modelling
Since no established control programmes have reached the
surveillance stage, no standard methods exist. Surveillance of
cysticercosis in pigs has been proposed as a practical, inexpensive,
and sensitive method for indirectly assessing human risk, and for
monitoring the effectiveness of community-based control pro-
grammes [87,89]. Infection in pigs is more prevalent than human
infection, and infection prevalence in pigs is subject to more rapid
change due to more rapid replacement of the pig population
compared to the human population [90]. Slaughterhouse
prevalence statistics are liable to underestimate the prevalence
of infection in endemic areas, as many pigs are not processed
through the formal slaughterhouse system. Indeed, if pig farmers
suspect that their pigs have cysticercosis they may avoid taking
them to the slaughterhouse [90]. An alternative approach that
has been suggested as a more effective way to assess changes in
the intensity of environmental contamination with T. solium eggs
is the placement of ‘‘sentinel’’ pigs from non-endemic areas in an
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area under surveillance and their monitoring by periodic serology
[91].
Human taeniasis usually has very low prevalence and human
cysticercosis may present years after infection, so neither of these
represent an appropriate target for active surveillance. Screening
of household contacts of cases may be a useful mean of
identification and treatment of tapeworm carriers [92,93].
Food-Borne Trematodiases
The inadequate state of diagnostic tests for zoonotic trematodes,
and particularly Clonorchis sinensis, Opisthorchis viverrini, Op. felineus,
Paragonimus spp., and other related fluke species, including
misdiagnosis of infecting species, underestimation of prevalence,
and inaccurate estimates of infection intensity, has been recently
reviewed [94]. A detailed discussion of the strengths and
weaknesses of diagnostic tests appropriate for diagnosis of food-
borne trematode infection is available in Text S6, and the research
priorities for food-borne trematode diagnosis are summarised in
Box 3.
Infection Intensity
As for intestinal nematodes, faecal egg counts do not correlate
particularly well with the actual worm burden [95]. In an autopsy
study aimed to assess the relationship between faecal egg count
and worm burden of Op. viverrini, worms were found in up to 20%
individuals with a negative faecal egg examination [96]. Although
a positive correlation was observed between worm burden and
faecal egg counts in heavier infections, a density-dependent effect
on excretion confounded the relationship.
Bringing New Helminth Diagnostic Tests to
Market
As outlined in this manuscript and accompanying supplemental
files, there is a significant literature on prototype diagnostic tests
for helminth infections. Once prototype diagnostic devices for
helminth infections reach an acceptable level of technical
performance, their further development beyond proof of concept
requires that a range of significant challenges be overcome. As is
the case in the more prominent diseases such as AIDS,
tuberculosis (TB), and malaria, the development of critically
needed diagnostic tests has assumed lower research priority
compared to other areas such as vaccine and drug development.
The lack of funding dedicated to development of diagnostics for
helminth infections remains a significant impediment, as discussed
in Boatin et al. [45] in this collection. This is a reflection of the
relatively small funding pool available for helminths overall (see
below).
The likely limited interest in commercialisation, a consequence
of the limited financial return, is a major impediment to the
development of diagnostic tests. This is due to a range of factors
including: a) the low priority for making a specific diagnosis of
most of these conditions in endemic settings; b) the low royalty for
licensing (,5% in most settings) [97]; and c) the significant costs
associated with the commercial scale manufacture and marketing
of such tests.
Further, the significant investment is required for diagnostic
tests to gain regulatory approval from the US Food and Drug
Administration (FDA) [98] or the European Union Medical
Device Safety Service (MDSS; http://www.mdss.com/IVDD/
ivddtoc.htm), and represents a further deterrent. While gaining
formal regulatory approval may not be essential for the
deployment of a new diagnostic test for helminth infections
or other NTDs, such approval carries significant advantages. A
minimum requirement for purchase is evidence of good
manufacturing practices, as documented by either compliance
with ISO 13485:2003 or 21 CFR 820 from the FDA. Once
such compliance has been demonstrated, it is likely to be easier
to gain financial support from donors and funders for pur-
chase of a diagnostic test for use in public health control
programmes.
Despite these challenges, examples exist of diagnostic devices or
platforms relevant to helminth infections and others NTDs that
have successfully reached market. These include circulating
antigen tests for filariasis [99,100], rapid diagnostic tests for
malaria [101], the k39 antibody detection test for leishmaniasis
[102], and the urinary CCA test for schistosomiasis [103]. Not well
documented in the scientific literature are the difficulties that each
of these platforms experienced in reaching market and then
maintaining a market presence. Of these, only a malaria rapid
diagnostic test from a single manufacturer (BinaxNOW Malaria
test kit; Inverness, Scarborough, Maine, United States) has gained
FDA approval as a diagnostic device.
Examination of the landscape of diagnostic tests and their
pathway to deployment therefore indicates that the standard
commercial pathway is not well suited to meeting the needs for
diagnostics to aid in the control of helminth parasites. Indeed, in
a recent review of the global investment for NTDs [104], the
sum of funding for research and development (R&D) for
diagnostic tests for helminth diseases was $US1.4 million, a
figure that represented 1.8% of total R&D funding for helminths
(Table 6). While this relative lack of investment is by no means
unique to these pathogens, it is of major importance in
consideration of the need to develop and deploy much-needed
new diagnostic tests for helminth infections. Indeed, it has
become clear that to reach the targets of the Millennium
Development Goals (MDGs) for many of the priority infectious
diseases such as TB, there is a major and unmet need for the
development of diagnostic tests.
A novel approach to bridging the gap between demonstrating
a technically satisfactory diagnostic assay, and bringing the
product in question to the market entails the formation of
organisations specifically tasked with this mission. The foremost
example of such a Product Development and Implementation
Partnership (PDIP) is the Foundation for Innovative New
Diagnostics (FIND; http://www.finddiagnostics.org), an organi-
sation that focuses on a small number of diseases including TB,
sleeping sickness, and malaria. It is supported by the World
Health Organization, the Bill & Melinda Gates Foundation, the
European Commission, the Government of The Netherlands,
UNITAID, DFID, and others.
As outlined by Murdoch in a FIND monograph [105], a
range of complex issues need to be dealt with to successfully
develop such diagnostics. These include: a) identifying specific
patients’ needs in developing countries and targeting products
to all the levels of the health system; b) understanding the
market—potential volumes, distribution of products, and end
user profiles; c) arranging the financial considerations to ensure
they cover both research and development costs; d) settling
issues regarding intellectual property rights for products with no
or limited financial return; e) finding the right manufacturing
approach and harnessing possibilities for technology transfer; f)
creating methods for evaluating the product through clinical
trials and for introducing it at country level; g) working with
governments to adapt national policies and approaches; h)
working with local laboratories to ensure they have the capacity
to use the products effectively; and i) working with donors and
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national governments to make sure tests can be purchased at
prices affordable for all.
It is apparent that for the successful development of the novel
diagnostic tests required for the control of helminth parasites,
similar approaches will be required. However, even if such a
model for development of diagnostic tests were implemented, a
system would need to be put in place to finance procurement, as
requiring the end user to pay will likely result in tests not being
used.
Concluding Remarks
Although a significant number of obstacles of a technical
nature impede the development of diagnostics appropriate to
support the ambitious programmes now in place to control the
NTDs in general, and the human helminthiases in particular,
there is good evidence that the tools are available to overcome
these obstacles. Whether the patchwork of activities as currently
being undertaken largely by enthusiastic researchers, for the
most part working in academic settings, will result in the
expeditious development of these much needed tests is uncertain.
As identified in the G-Finder report [104], the expenditure on
R&D for NTD diagnostics represents only a small proportion of
the funding expended in these areas, and is yet an even smaller
proportion of the operational costs of undertaking the compre-
hensive parasite control programmes that are currently being
advocated or implemented [3,24]. Many lessons can be learned
from the initiative to improve the development and public health
deployment of rapid diagnostics for malaria, led by TDR and
FIND. Although funding for assay development is needed, the
largest needs relate to programmatic leadership and support to
bridge the gap between the demonstration of satisfactory
technical performance of diagnostic platforms in field or clinical
settings, and their deployment in large-scale public health
programmes for the control and elimination of human helmin-
thiases.
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